LENSAR (NASDAQ:LNSR) Posts Earnings Results, Beats Estimates By $0.26 EPS

LENSAR (NASDAQ:LNSR) posted its quarterly earnings data on Thursday. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.26, Zacks reports. LENSAR had a negative return on equity of 183.19% and a net margin of 50.94%.

Here are the key takeaways from LENSAR’s conference call:

• Q2 revenue increased 18% year over year to $16.5 million, while recurring revenue rose 20% to $13.7 million and procedure revenue grew 23% to $10.2 million.
• LENSAR placed 10 ALLY systems during the quarter, expanding the global installed base to approximately 445 systems, with 13 ALLY systems in backlog; procedure volume increased 13% to 58,682 and U.S. procedure market share reached 24.1%.
• The company reported its strongest adjusted EBITDA performance to date at $3.6 million, supported by revenue growth, a greater mix of recurring revenue, and lower expenses; gross margin was 52% excluding a $1.1 million tariff refund.
• Cash and equivalents declined to $13.6 million from $18 million at year-end 2025, and management expects operating expenses to rise toward historical levels as it increases commercial investment, creating potential variability in EBITDA over the next several quarters.
• Management cautioned that third-quarter cataract procedure volumes are historically lower because of seasonal holidays and vacations, while rebuilding overseas distributor relationships is expected to take several quarters.

LENSAR Stock Performance

Shares of LENSAR stock traded up $1.76 during midday trading on Thursday, reaching $8.05. 1,923,914 shares of the company’s stock traded hands, compared to its average volume of 93,802. LENSAR has a 12 month low of $4.95 and a 12 month high of $12.96. The stock has a 50 day moving average of $5.79 and a 200-day moving average of $7.40. The company has a market cap of $98.92 million, a PE ratio of -13.83 and a beta of 0.89.

Hedge Funds Weigh In On LENSAR

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its holdings in shares of LENSAR by 129.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock valued at $25,000 after acquiring an additional 1,131 shares during the period. JPMorgan Chase & Co. raised its position in shares of LENSAR by 584.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company’s stock valued at $62,000 after buying an additional 3,991 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in LENSAR in the second quarter worth approximately $68,000. New York State Common Retirement Fund purchased a new stake in LENSAR in the second quarter valued at $105,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of LENSAR in the 3rd quarter valued at $125,000. Hedge funds and other institutional investors own 40.15% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Wall Street Zen downgraded shares of LENSAR from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. BTIG Research increased their target price on LENSAR from $7.00 to $9.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings restated a “sell (d+)” rating on shares of LENSAR in a research report on Friday, August 7th. Finally, Lake Street Capital reaffirmed a “buy” rating on shares of LENSAR in a research note on Thursday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, LENSAR currently has an average rating of “Hold” and a consensus target price of $9.50.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.